Machine Learning‐Based Discovery of a Novel Noncovalent MurA Inhibitor as an Antibacterial Agent
Chemical Biology & Drug Design · 2025-03 · 105 (3)
DOI: 10.1111/cbdd.70084 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Biology & Drug Design, online erschienen am 12.03.2025. Verfasst von Qingxin Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Jiangsu Ocean University, Lianyungang, Jiangsu, China. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Enzyme Inhibitors, Machine Learning, Molecular Docking Simulation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: Priority Academic Program Development of Jiangsu Higher Education Institutions.
Abstract (Originalsprache)
The bacterial cell wall is crucial for maintaining the integrity of bacterial cells. UDP‐N‐acetylglucosamine 1‐carboxyethylene transferase (MurA) is an important enzyme involved in bacterial cell wall synthesis. Therefore, it is an important target for antibacterial drug research. Although many MurA inhibitors have been discovered, only fosfomycin is still used as a MurA inhibitor in clinical practice. Owing to the long‐term use of fosfomycin, the emergence of fosfomycin resistance is worrisome. Therefore, it is still necessary to discover new MurA inhibitors with different types of action than fosfomycin. In this study, we used AutoMolDesigner to construct a machine learning model combined with molecular docking to screen for noncovalent MurA inhibitors. We subsequently conducted the MurA inhibition activity assay and identified compound L16 (N‐(3‐(benzo[d]oxazol‐2‐yl)‐4‐hydroxyphenyl) carbamoyl‐4‐methylbenzamide) as a moderately active MurA inhibitor (IC 50 = 26.63 ± 1.60 μM). The compound was structurally different from other known MurA inhibitors. We used molecular dynamics simulation to reveal possible interactions between the compound and MurA. In addition, we also found that compound L16 was nontoxic to human liver cancer cells (HepG2) (IC 50 > 100 μM). In conclusion, through virtual screening and in vitro biological evaluation, we identified a novel structural type of MurA inhibitor which may become a candidate drug for inhibiting bacterial cell wall synthesis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Jiangsu Ocean University, Lianyungang, Jiangsu, China.
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, China.
- Department of Pharmacy, Lianyungang Affiliated Hospital of Nanjing University of Chinese Medicine, Lianyungang, China.
ORCID-Profile: Qingxin Liu
Förderung
- Priority Academic Program Development of Jiangsu Higher Education Institutions
Zitieren
APA
Liu, Q., Luo, A., Jin, H., Si, X., & Li, M. (2025). Machine Learning‐Based Discovery of a Novel Noncovalent MurA Inhibitor as an Antibacterial Agent. Chemical Biology & Drug Design, 105(3). https://doi.org/10.1111/cbdd.70084
Vancouver
Liu Q, Luo A, Jin H, Si X, Li M. Machine Learning‐Based Discovery of a Novel Noncovalent MurA Inhibitor as an Antibacterial Agent. Chemical Biology & Drug Design. 2025;105(3). doi:10.1111/cbdd.70084
BibTeX
@article{Liu2025,
author = {Liu, Qingxin and Luo, Aoqi and Jin, Hongwei and Si, Xinxin and Li, Ming},
title = {Machine Learning‐Based Discovery of a Novel Noncovalent MurA Inhibitor as an Antibacterial Agent},
journal = {Chemical Biology & Drug Design},
year = {2025},
volume = {105},
number = {3},
doi = {10.1111/cbdd.70084}
}
EUVIMED